Free Trial
→ A Worldwide Gold Lockdown Is Now Underway (From Stansberry Research) (Ad)tc pixel

ArriVent BioPharma (NASDAQ:AVBP) Earns Sell (D-) Rating from Weiss Ratings

Written by MarketBeat
October 25, 2025
ArriVent BioPharma logo with Medical background

Key Points

  • ArriVent BioPharma (NASDAQ:AVBP) was given a "sell (D-)" rating by Weiss Ratings, while other analysts have varied ratings including one "Strong Buy" and multiple "Buy" ratings.
  • The company's stock is currently trading at $18.60, which is below its one-year high of $36.37 and has a market capitalization of approximately $754.58 million.
  • ArriVent reported an earnings per share (EPS) of ($(0.90)) for the last quarter, missing analysts' expectations by $(0.20).
  • Five stocks to consider instead of ArriVent BioPharma.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Other equities analysts have also issued research reports about the company. HC Wainwright reaffirmed a "buy" rating and issued a $42.00 price objective (up previously from $40.00) on shares of ArriVent BioPharma in a research note on Tuesday, August 12th. Zacks Research cut shares of ArriVent BioPharma from a "hold" rating to a "strong sell" rating in a research report on Monday, October 13th. B. Riley upgraded shares of ArriVent BioPharma to a "strong-buy" rating in a research report on Monday, August 25th. The Goldman Sachs Group upgraded shares of ArriVent BioPharma to a "buy" rating and set a $33.00 price objective on the stock in a research report on Thursday, July 10th. Finally, Citigroup reiterated a "buy" rating and set a $33.00 price objective (down previously from $40.00) on shares of ArriVent BioPharma in a research report on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $39.14.

View Our Latest Analysis on ArriVent BioPharma

ArriVent BioPharma Trading Up 2.8%

NASDAQ AVBP traded up $0.51 on Friday, reaching $18.60. 292,538 shares of the stock were exchanged, compared to its average volume of 270,184. ArriVent BioPharma has a one year low of $15.47 and a one year high of $36.37. The firm has a market capitalization of $754.58 million, a PE ratio of -4.63 and a beta of 1.11. The company's 50-day simple moving average is $19.25 and its two-hundred day simple moving average is $20.22.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.20). Sell-side analysts forecast that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its position in ArriVent BioPharma by 31.0% during the second quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company's stock valued at $56,000 after acquiring an additional 609 shares during the last quarter. Tower Research Capital LLC TRC increased its position in ArriVent BioPharma by 571.6% during the second quarter. Tower Research Capital LLC TRC now owns 6,669 shares of the company's stock valued at $145,000 after acquiring an additional 5,676 shares during the last quarter. Walleye Capital LLC bought a new position in ArriVent BioPharma during the second quarter valued at $206,000. Brevan Howard Capital Management LP bought a new position in ArriVent BioPharma during the second quarter valued at $209,000. Finally, Jane Street Group LLC bought a new position in ArriVent BioPharma during the first quarter valued at $189,000. Institutional investors own 9.48% of the company's stock.

About ArriVent BioPharma

(Get Free Report)

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

Further Reading

Analyst Recommendations for ArriVent BioPharma (NASDAQ:AVBP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ArriVent BioPharma Right Now?

Before you consider ArriVent BioPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.

While ArriVent BioPharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.